Table 1 Characteristics of the HCV genotype 1 and 2 infected patients receiving PEG-IFNα-RBV therapy

Number of patients

265

163

102

-

195

178

17

-

Gender (males/females)

129/136

84/79

45/57

0.241

88/107

81/97

7/10

0.732

Age (mean ± SD)

52.17 ± 10.27

50.69 ± 10.60

54.52 ± 9.29

0.002^a

51.62 ± 10.89

51.15 ± 11.16

56.47 ± 5.86

0.050^a

BMI (mean ± SD)

24.6 ± 3.1

24.2 ± 2.9

25.2 ± 3.3

0.026^a

24.5 ± 3.5

24.5 ± 3.6

24.5 ± 2.7

0.863^a

Degree of inflammatory activity (A0/A1-3) ^c

35/230

17/146

18/84

0.0913^b

22/173

18/160

4/13

0.0948^b

Stage of fibrosis (F0/F1-4) ^c

16/249

6/157

10/92

0.0417^b

10/185

7/171

3/14

0.0143^b

AST (U/L) (mean ± SD)

76.15 ± 41.24

90.91 ± 61.12

0.049^a

84.26 ± 63.45

78.12 ± 34.03

0.744^a

ALT (U/L) (mean ± SD)

118.56 ± 75.99

108.05 ± 74.97

0.328^a

120.67 ± 104.63

100.71 ± 44.76

0.822^a

Platelet (× 10 ³ /μl) (mean ± SD)

176.4 ± 56.7

154.9 ± 59.5

0.002^a

174.4 ± 52.4

125.5 ± 41.8

0.001^a

Viral load (× 10 ⁶ )

12.1 ± 16.4

11.0 ± 16.5

13.9 ± 16.2

0.001^a

11.0 ± 19.0

10.3 ± 17.8

18.4 ± 27.9

0.334^a